AIMIA ANNOUNCES DIRECTOR RESIGNATION
TORONTO, Sept. 25, 2023 /CNW/ - Aimia Inc. (TSX: AIM) ("Aimia" or the "Company") today announces that Jon Mattson has provided notice of his intention to resign as a Director of the Company, effective today. He will, however, continue to provide oversight and consulting services with Aimia and Aimia's most recent investments, Tufropes and Bozzetto.
"Since joining Aimia's board of directors, I've been privileged to have a part in its development and transformation. Aimia and its businesses have my continued and ongoing support and I look forward to seeing Aimia's continued evolution," said Jon Mattson.
"On behalf of our management team and board of directors I want to thank Jon for his contribution to Aimia over the years and wish him the best on his current and future endeavors," said Philip Mittleman, Chief Executive Officer of Aimia.
About AimiaAimia Inc. is a holding company with a focus on making long-term investments in public and private companies, on a global basis, through controlling or minority stakes.
For more information about Aimia, visit www.aimia.com.
SOURCE Aimia Inc.
Ausgewählte Hebelprodukte auf Hemispherx Biopharma
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Hemispherx Biopharma
Der Hebel muss zwischen 2 und 20 liegen
Aktuelle Hemispherx Biopharma Aktie News
Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.
Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv
Hemispherx Biopharma Analysen
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Hemispherx Biopharma nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
Keine Analysen gefunden.